How to Forecast Pharmacy Cash Flow Risk From Drug Pricing Policy Changes

The 340B program generates 25-50% of pharmacy margins for many participating organizations. That revenue has always arrived at the point of sale, baked into the discounted acquisition cost. Now, two converging federal policy shifts threaten to change when and whether those dollars show up at all.

• HRSA’s 340B Rebate Model Pilot, which is currently paused, would replace upfront discounts with post-sale manufacturer rebates. A federal court vacated the pilot on February 10, 2026, but the challenge succeeded on procedural grounds, not on authority. The 340B statute still permits discounts via “rebate or discount,” and HRSA has issued a new Request for Information signaling the agency is rebuilding its case.
• The Inflation Reduction Act’s Medicare Drug Price Negotiation Program began compressing reimbursement on 10 high-spend Part D drugs on January 1, 2026, with 15 more drugs selected for 2027.

Hospital cash reserves have fallen roughly 28% since 2022, according to AHA and Syntellis data. Hospital average operating margins dropped from 3.4% in January to 2.5% in February, but remained above 2024 averages, per Kaufman Hall’s National Hospital Flash Report. At those numbers, a delay of even 30 days on rebate payments for high-volume drugs could force difficult choices between funding patient programs and covering working capital gaps.

The question facing pharmacy leaders is whether your organization can quantify the exposure before the next policy change lands.

Step 1: Calculate Your Monthly WAC Exposure

Under a rebate model, covered entities would purchase at WAC instead of the 340B ceiling price and submit claims for reimbursement afterward. Research estimates that this shift could produce temporary drug spend spikes of 500% to 5,000% on affected medications. Sizing your specific exposure takes three inputs:

1. Identify formulary overlap. Flag every drug that appears on the IRA’s negotiated drug list and the original rebate pilot scope. HRSA has signaled potential expansion through 2027, so include the 15 drugs selected for next year’s negotiation as well.
2. Pull your current 340B acquisition cost and WAC for each. The difference is your per-unit float under a rebate model.
3. Multiply by monthly dispensing volume. The result is your gross monthly cash exposure.

Here is how that calculation could look for a mid-size health system purchasing three of the original pilot drugs:

Drug	Monthly Units	340B Cost/Unit	WAC/Unit	Monthly 340B Spend	Monthly WAC Spend	Monthly Float
Eliquis	4,000	$3.50	$17.00	$14,000	$68,000	$54,000
Xarelto	2,500	$4.20	$18.50	$10,500	$46,250	$35,750
Entresto	1,800	$5.00	$19.80	$9,000	$35,640	$26,640
Total Spend				$33,500	$149,890	$116,390

Note: Unit costs are illustrative. Your actual 340B ceiling prices and WAC will vary by contract and NDC.

That $116,390 per month is cash your organization would need to front before a single rebate dollar returns. For a large health system dispensing across dozens of sites, the number can reach seven figures monthly.

Bluesight’s CostCheck compares pricing across WAC, post-rebate 340B, and MFP pricing paths before purchase, giving pharmacy teams a pre-decision view of true cost under each scenario.

Step 2: Model Rebate Timing Scenarios

Under the proposed pilot, manufacturers had 10 calendar days to pay approved rebates. But the clock starts after submission, and the submission process itself takes weeks for most organizations. Before a single rebate claim reaches the manufacturer, pharmacy teams must:

• Aggregate claims data from TPAs, EHRs, and pharmacy management systems
• Validate patient eligibility, prescriber relationships, and site registration against 340B requirements
• Reconcile discrepancies across data sources before packaging submission-ready files

Denied or disputed claims add a second delay. Every rejected claim under a rebate model is not a delayed payment; it is a permanent loss of savings.

Apply your monthly float from Step 1 across three timing scenarios to see the range of working capital impact. Using the $116,390 example:

Scenario	Rebate Turnaround	Cash Tied Up	Assumptions
Best case	10 days	~$38,800	Clean submission, no disputes, manufacturer pays within pilot timeline
Realistic	45 days	~$174,585	Submission delays from TPA/EHR data aggregation and reconciliation
Worst case	90 days	~$349,170	Denied or disputed claims requiring resubmission or appeals

Formula: (Monthly float ÷ 30) × days until rebate receipt = cash tied up at any given time. In the realistic scenario, you carry roughly 1.5 months of float simultaneously because new purchases accumulate while prior claims await payment.

At a health system dispensing 10x this volume, the realistic scenario means $1.7 million perpetually tied up in rebate receivables. Layer that against operating margins of 2.5% and you can see how quickly the float consumes available working capital.

Bluesight’s 340BCheck audits 100% of transactions across TPA and EHR data prior to submission, while CostCheck flags invoices requiring rebate submission and monitors reconciliation windows. Together, they move organizations toward the best-case scenario by reducing the submission delays and denial rates that push turnaround into the 45-90 day range.

Step 3: Quantify Your Margin-at-Risk From IRA Compression

The IRA’s Medicare Drug Price Negotiation Program is already compressing 340B margins on the first 10 negotiated drugs, even under the current upfront discount model. For roughly 85% of active NDCs in those drugs, the 340B ceiling price remains lower than the MFP. But the IRA’s non-duplication provision prevents manufacturers from providing both a 340B discount and an MFP on the same claim. For Medicare Part D prescriptions filled at 340B prices, that reduces the net margin and shrinks the spread between acquisition cost and what Medicare pays.

To estimate the impact:

1. Pull your Medicare Part D claim volume for the 10 negotiated drugs (and the 15 selected for 2027).
2. Compare your current 340B spread (reimbursement minus acquisition cost) against the projected post-MFP spread for each drug.
3. Calculate the annual margin reduction. This is savings your organization will lose regardless of whether the rebate model returns.

This margin compression affects the program’s 340B savings fund. Safety-net hospitals rely on those dollars to support:

• Uncompensated care for uninsured and underinsured patients
• Outpatient clinics and community health services
• Medication access and patient assistance programs

When you combine the IRA margin reduction (happening now) with the potential rebate float (coming next), you get the full picture of your organization’s 340B financial exposure.

Step 4: Stress-Test Your Compliance Readiness

Run a 340B compliance audit under the current upfront model to validate the assumptions behind your forecast. The timing scenarios in Step 2 assume your claims are clean and defensible. If they are not, your actual cash exposure is worse than the model predicts, because every rejected claim under a rebate model becomes a permanent revenue loss rather than a corrective action item.

HRSA audits in FY 2024 found that 18% required repayment to manufacturers and 62% cited incorrect OPAIS records. A separate Bluesight survey found that 76% of compliance managers expect regulatory oversight to increase over the next two to three years. If your organization audits fewer than 100% of transactions today, your forecast should include a denial-rate adjustment:

Adjusted float = Monthly float × (1 + estimated denial rate)

A 5% denial rate on the $116,390 example adds $5,820 per month in permanently lost savings. At scale, that compounds quickly. Bluesight’s 340BCheck automates 100% transaction auditing, catches diversion and duplicate discount errors before they become audit findings, and syncs OPAIS records daily to prevent the recordkeeping errors that account for the majority of HRSA violations.

Running a full compliance audit now gives you the denial-rate input your forecast needs and fixes the gaps before they carry financial consequences under a rebate model.

Put the Number in Front of Your CFO

The four steps above produce a dollar figure representing your organization’s total 340B cash flow exposure under various policy scenarios. That number belongs in front of your CFO, your pharmacy director, and your compliance team today, not the day a new pilot is announced.

HRSA is rebuilding its administrative record, not abandoning the rebate concept. A redesigned pilot could move faster than the first attempt.

Organizations that unify procurement, compliance, and finance into a single operational framework will adapt regardless of when the next policy shift arrives. Those still managing cost, supply, and compliance in separate silos risk falling into a cycle of reactive firefighting that drains labor hours and erodes margins. See how 340BCheck and CostCheck give your team closed-loop visibility from purchase to rebate receipt.